No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 370-377

  Yin, Ming ^a   Yan, Jingrong ^b   Voutsina, Alexandra ^c   Tibaldi, Carmelo ^d   Christiani, David C ^e   Heist, Rebecca S ^f   Rosell, Rafael ^g   Booton, Richard ^h   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CRETE   (Greece)

^d Azienda USL 6 Livorno   (Italy)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; DNA repair; Meta analysis; Pharmacogenetics; Platinum

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; CARBOPLATIN; CISPLATIN; CYSTEINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTAMINE; LYSINE; THREONINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; GENETIC ASSOCIATION; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 79955471779     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.011     Document Type: Article

References (36)

1. Bahl A., Falk S. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?. Br J Cancer 2001, 84:1143-1145.
2. Shellard S.A., Fichtinger-Schepman A.M., Lazo J.S., Hill B.T. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993, 4:491-500.
3. Ma H., Xu L., Yuan J., Shao M., Hu Z., Wang F., et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics 2007, 17:417-423.
4. Yu J.J., Lee K.B., Mu C., Li Q., Abernathy T.V., Bostick-Bruton F., et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000, 16:555-560.
5. Duell E.J., Wiencke J.K., Cheng T.J., Varkonyi A., Zuo Z.F., Ashok T.D., et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000, 21:965-971.
6. Lunn R.M., Helzlsouer K.J., Parshad R., Umbach D.M., Harris E.L., Sanford K.K., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21:551-555.
7. Vilmar A., Sorensen J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 2009, 64:131-139.
8. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.
9. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., et al. Correlation of CDA ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 14:1797-1803.
10. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
11. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
12. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
13. Lin D.Y., Zeng D. Meta-analysis of genome-wide association studies: no efficiency gain in using individual participant data. Genet Epidemiol 2009, 34:60-66.
14. Pillot G.A., Read W.L., Hennenfent K.L., Marsh S., Gao F., Viswanathan A., et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 2006, 1:972-978.
15. Gandara D.R., Kawaguchi T., Crowley J., Moon J., Furuse K., Kawahara M., et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009, 27:3540-3546.
16. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-4902.
17. Bosken C.H., Wei Q., Amos C.I., Spitz M.R. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002, 94:1091-1099.
18. Qiao Y., Spitz M.R., Guo Z., Hadeyati M., Grossman L., Kraemer K.H., et al. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 2002, 509:165-174.
19. Spitz M.R., Wu X., Wang Y., Wang L.E., Shete S., Amos C.I., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001, 61:1354-1357.
20. Wei S.Z., Zhan P., Shi M.Q., Shi Y., Qian Q., Yu L.K., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2010, (February). Epub ahead of print.
21. Kalikaki A., Kanaki M., Vassalou H., Souglakos J., Voutsina A., Georgoulias V., et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:118-123.
22. Li F., Sun X., Sun N., Qin S., Cheng H., Feng J., et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010, (March). Epub ahead of print.
23. Chen S., Zhang J., Wang R., Luo X., Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010, (June). Epub ahead of print.
24. Ye N., Bianchi M.S., Bianchi N.O., Holmquist G.P. Adaptive enhancement and kinetics of nucleotide excision repair in humans. Mutat Res 1999, 435:43-61.
25. Booton R., Ward T., Heighway J., Taylor P., Power F., Ashcroft L., et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 2006, 106:2421-2427.
26. Camps C., Sarries C., Roig B., Sanchez J.J., Queralt C., Sancho E., et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003, 4:237-241.
27. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
28. Su D., Ma S., Liu P., Jiang Z., Lv W., Zhang Y., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56:281-288.
29. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
30. Park S.Y., Hong Y.C., Kim J.H., Kwak S.M., Cho J.H., Lee H.L., et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 2006, 23:489-498.
31. de las Penas R., Sanchez-Ronco M., Alberola V., Taron M., Camps C., Garcia-Carbonero R., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17:668-675.
32. Okuda K., Sasaki H., Hikosaka Y., Kawano O., Yukiue H., Yano M., et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 2009.
33. Chen S., Huo X., Lin Y., Ban H., Li W., Zhang B., et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010, 213:140-145.
34. Zhou C., Ren S., Zhou S., Zhang L., Su C., Zhang Z., et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 2010, (May). Epub ahead of print.
35. Yao C.Y., Huang X.E., Li C., Shen H.B., Shi M.Q., Feng J.F., et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 2009, 10:859-864.
36. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004, 22:2594-2601.